Creating a commercial category with one weak first mover is still a good way to accelerate real breakthroughs.

The logic is plausible, and capital often follows early market creation. But it can also misallocate enormous resources toward a flawed target or a politically toxic reimbursement model.

The FDA can responsibly use approval to create a market when Congress or CMS fail to fix system incentives.

That asks the FDA to solve industrial-policy and payment-design problems with a tool that is supposed to police safety and efficacy. It is a workaround, not a clean regulatory principle.

If even skeptical experts would let a loved one try the drug, the approval is easier to justify.

That is emotionally intuitive, but private willingness to gamble on hope is not the same standard as public regulatory endorsement.

Regulators should explain controversial approvals in plain English when trust is at stake.

That would not solve the evidence problem, but it is an important legitimacy requirement in cases where the agency is clearly stretching past consensus.

Terminal or degenerative patients with few options should get more regulatory latitude even when evidence is inconclusive.

That principle is broadly reasonable. The problem here is that broad approval and reimbursement are much bigger steps than limited expanded access.

Post-market observation can responsibly function as a practical 'stage four' filter for a drug like Aduhelm.

That can work in some settings, but once a treatment is normalized and widely paid for, it becomes much harder politically and clinically to unwind.

Approving a weakly supported drug makes future evidentiary standards for similar drugs harder to defend.

That risk is real whenever regulators override a skeptical advisory process on a high-profile therapy. The more politically charged the disease area, the more precedent matters.

Patients should not be offered expensive, system-wide reimbursed treatments on the back of contested surrogate evidence alone.

Compassion matters, but once public payers and clinical norms are involved, the burden of proof is much higher than a private, self-funded moonshot.

State-backed commercial contracting is a better way to push space innovation than having government build and operate everything itself.

The NASA commercial-crew experience gives this argument real support. Competition plus milestone contracts usually create better incentives than a pure state-operated monopoly.

Space is too vast for durable ownership or domination to look like terrestrial monopoly control.

The literal ownership claim is fairer than Jason allows, but control over key orbital lanes, launch capability, and satellite infrastructure can still create real strategic dominance.

Bezos's first-crew flight was still risky enough that a rational founder should have sat it out.

The concern was not crazy in June 2021, but the later outcome and the mission-preparation evidence make the call look more defensible than reckless.

Strategic rivalry in space means the U.S. should treat launch and orbital capability as a serious national-interest domain.

That is right in the abstract. The military and infrastructure stakes in space are plainly real even if Jason overdramatizes them at points.

A first crewed suborbital flight is too risky to justify for someone in Bezos's position.

The caution is understandable, but the subsequent outcome and the mission-preparation record suggest the decision was not obviously reckless on the evidence available.

Public confidence in a space-tourism product can be built without the founder personally flying early.

That is true in principle. The founder's participation helps branding and signaling, but it is not the only way to build trust.

Internal test-flight data available to Bezos and Blue Origin mattered more than public anecdotes about earlier failures.

That is the right way to think about aerospace risk when the current system has accumulated more relevant evidence than the public can easily see.

A founder flying first is a meaningful signal that management trusts the hardware.

It is not proof of safety, but it is a strong reputational signal because the founder bears the same downside as the product's future customers.

Access to cheap, collateralized leverage is a major reason wealth compounds faster at the top than in the middle class.

That is a strong and durable insight. Scale, collateral, and financing terms matter enormously in compounding.

Publishing tax returns would reduce some of the system's shadiest behavior even if it would not change the law itself.

Transparency would not eliminate the structural asymmetry, but it would make narrative arbitrage and reputationally fragile tactics harder to hide.

A leak that vivid will move public opinion faster than any dry white paper on tax design.

That is usually how redistribution politics actually works. Narrative shocks often matter more than technical memos.

The U.S. was on a near-straight path from the leak to a generalized wealth tax.

The leak clearly energized the debate, but legal, constitutional, and political obstacles kept the path far messier than a straight-line forecast.

The possibility of liquidation and margin collapse materially limits how abusive the borrow-against-assets strategy can become.

Risk matters, but the richest borrowers also have the strongest collateral, the best financing terms, and the most room to survive volatility.

Borrowing against appreciated assets is not fundamentally different from ordinary households using home-equity lines of credit.

The basic mechanism is analogous, but the scale, terms, and compounding opportunities are radically different.

Much of the public outrage came from conflating unrealized appreciation with taxable income.

That was plainly part of the reaction. Even critics who want the law changed often begin by describing a legal distinction that many casual readers did not understand well.

Explaining the mechanics materially weakens the case that the system is unjust.

It weakens sloppy rhetoric, but it does not fully answer the fairness critique. A system can work as written and still produce politically destabilizing outcomes.

Once the inflation scare faded, builders had the capital and incentive to bring enough supply online quickly.

Even aside from rates, housing supply was constrained by zoning, labor, materials, and financing conditions. A quick builder-led normalization was too optimistic.

The 2021 inflation signal was mostly temporary rather than the start of a more durable macro problem.

The later path of inflation, Federal Reserve tightening, and mortgage rates makes this call look materially wrong in hindsight.

Housing scarcity severe enough to lock out young families would become politically impossible to ignore.

That proved true. Housing affordability became a durable national complaint and a repeated campaign issue.

Political pressure alone would be enough to break entrenched land-use and permitting constraints quickly.

Pressure helped move the conversation, but the policy machine remained slow, fragmented, and highly local.

Government debt and loose monetary policy could overpower technology's deflationary force for a meaningful period.

That is broadly what happened. Technology remained disinflationary in some domains, but it did not prevent the overall inflation shock or the aggressive policy response.

Housing stress could become a populist political issue on both left and right if ownership kept moving out of reach.

That diagnosis aged well. Housing affordability and investor ownership became major cross-ideological complaints.